Insulin receptor substrate-1 and Golgi phosphoprotein 3 are downstream targets of miR-126 in esophageal squamous cell carcinoma

Oncology Reports

Volumn 32, Issue 3, 2014, Pages 1225-1233

  Li, Haomiao ^a   Meng, Fanyu ^a   Ma, Jun ^a   Yu, Yongkui ^a   Hua, Xionghuai ^a   Qin, Jianjun ^a   Li, Yin ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Clinicopathological characteristics; Esophageal squamous cell carcinoma; Golgi phosphoprotein 3; Insulin receptor substrate 1; MiR 126

Indexed keywords

GOLGI PHOSPHOPROTEIN 3; INSULIN RECEPTOR SUBSTRATE 1; MICRORNA 126; PHOSPHOPROTEIN; UNCLASSIFIED DRUG; GOLPH3 PROTEIN, HUMAN; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MICRORNA; MIRN126 MICRORNA, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIGRATION INHIBITION; ONLINE SYSTEM; PRIORITY JOURNAL; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; CELL MOTION; ESOPHAGUS TUMOR; GENETICS; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; MEMBRANE PROTEINS; MICRORNAS; NEOPLASM INVASIVENESS;

EID: 84919964878     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3327     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
3. Mathé EA, Nguyen GH, Bowman ED, et al: MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 15: 6192-6200, 2009.
4. Song QK, Li J, Jiang HD, He YM, Zhou XQ and Huang CY: Esophageal cancer mortality during 2004-2009 in Yanting County, China. Asian Pac J Cancer Prev 13: 5003-5006, 2012.
5. Fareed KR, Kaye P, Soomro IN, et al: Biomarkers of response to therapy in oesophago-gastric cancer. Gut 58: 127-143, 2009.
6. Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450, 2006. (Pubitemid 44430905)
7. Pillai RS: MicroRNA function: multiple mechanisms for a tiny RNA? RNA 11: 1753-1761, 2005.
8. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005. (Pubitemid 40094598)
9. Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell 122: 6-7, 2005. (Pubitemid 40977933)
10. Rosenfeld N, Aharonov R, Meiri E, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26: 462-469, 2008. (Pubitemid 351501813)
11. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714, 2009.
12. Schmidt M, De Maziere A, Smyczek T, et al: The role of Egfl7 in vascular morphogenesis. Novartis Found Symp 283: 18-28; discussion 28-36, 238-241, 2007.
13. Schmidt M, Paes K, De Maziere A, et al: EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development 134: 2913-2923, 2007. (Pubitemid 47386904)
14. Li XM, Wang AM, Zhang J and Yi H: Downregulation of miR-126 expression in colorectal cancer and its clinical significance. Med Oncol 28: 1054-1057, 2011.
15. Yang J, Lan H, Huang X, Liu B and Tong Y: MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. PLoS One 7: e42978, 2012.
16. Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K and Yuasa Y: MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS One 6: e16617, 2011.
17. Sasahira T, Kurihara M, Bhawal UK, et al: Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer 107: 700-706, 2012.
18. Crawford M, Brawner E, Batte K, et al: MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 373: 607-612, 2008.
19. Ye P, Liu J, He F, Xu W and Yao K: Hypoxia-induced deregulation of miR-126 and its regulative effect on VEGF and MMP-9 expression. Int J Med Sci 11: 17-23, 2014.
20. Li N, Li X, Huang S, Shen S and Wang X: miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene. Zhong Nan Da Xue Xue Bao Yi Xue Ban 38: 809-817, 2013 (In Chinese).
21. Lu YY, Sweredoski MJ, Huss D, Lansford R, Hess S and Tirrell DA: Prometastatic GPCR CD97 is a direct target of tumor suppressor microRNA-126. ACS Chem Biol 9: 334-338, 2014.
22. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
23. Zhang Y, Wang Z, Chen M, et al: MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer 11: 23, 2012.
24. Zhao X, Dou W, He L, et al: MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene 32: 1363-1372, 2013.
25. Tsuchiya S: The role of microRNA-210 in esophageal squamous cell carcinoma. Yakugaku Zasshi 132: 1069-1073, 2012 (In Japanese).
26. Yang R, Dick M, Marme F, et al: Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast Cancer Res Treat 127: 549-554, 2011.
27. White MF: IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283: E413-E422, 2002.
28. Porter HA, Perry A, Kingsley C, Tran NL and Keegan AD: IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. Cancer Lett 338: 239-248, 2013.
29. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T and Baserga R: Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 282: 32582-32590, 2007. (Pubitemid 350159311)
30. Yin Y, Yan ZP, Lu NN, et al: Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1. Biochim Biophys Acta 1829: 239-247, 2013.
31. Scott KL, Kabbarah O, Liang MC, et al: GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 459: 1085-1090, 2009.
32. Hua X, Yu L, Pan W, et al: Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol 7: 127, 2012.
33. Hu BS, Hu H, Zhu CY, Gu YL and Li JP: Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour Biol 34: 515-520, 2013.
34. Wang JH, Chen XT, Wen ZS, et al: High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. PLoS One 7: e45622, 2012.
35. Li N, Tang A, Huang S, et al: MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway. Mol Cell Biochem 380: 107-119, 2013.